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BACKGROUND: Pancreatic cancer (PC) surveillance is currently offered to individuals with a genetic predisposition
to PC, but routinely used radiological screening modalities are not entirely reliable in detecting early-stage PC or its
precursor lesions. We recently identified a discriminating PC biomarker signature in a sporadic patient cohort. In
this study, we investigated if protein profiling can accurately distinguish PC from non-PC in a pancreatic
surveillance cohort of genetically predisposed individuals. METHODS: Serum samples of 66 individuals with a
CDKN2A germline mutation who participated in the pancreatic surveillance program (5 cases, 61 controls) were
obtained following a standardized protocol. After sample clean-up, peptide and protein profiles were obtained on
an ultrahigh-resolution matrix-assisted laser desorption/ionization–Fourier transform ion cyclotron resonance mass
spectrometry platform. A discriminant score for each sample was calculated with a previously designed prediction
rule, and the median discriminant scores of cases and controls were compared. Individuals with precursor lesions
of PC (n = 4) and individuals with a recent diagnosis of melanoma (n = 4) were also separately considered.
RESULTS: Cases had a higher median discriminant score than controls (0.26 vs 0.016; P = .001). The only
individual with pathologically confirmed precursor lesions of PC could also be clearly distinguished from controls,
and having a (recent) medical history of melanoma did not influence the protein signatures. CONCLUSIONS:
Peptide and protein signatures are able to accurately distinguish PC cases from controls in a pancreatic
surveillance setting. Mass spectrometry–based protein profiling therefore seems to be a promising candidate for
implementation in the pancreatic surveillance program as an additional screening modality.
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Pancreatic cancer (PC) is one of the most lethal cancers, with a 5-year
survival rate of only 5% [1]. The first clinical symptoms generally
appear relatively late when the tumor is already in an advanced
stage. To improve prognosis, PC has to be detected at an earlier
stage in which curative surgical resection is still possible. Therefore, in
the last decade, pancreatic surveillance programs for high-risk
individuals have been set up, aimed at detecting early-stage PC or
relevant precursor lesions in individuals with a genetic predisposition
to PC [2].
At the Leiden University Medical Center (LUMC), such a
pancreatic surveillance program was initiated in the year 2000 for
individuals with a CDKN2A germline mutation [3]. These
individuals have a familial predisposition for developing cutaneous
melanoma, a condition known as familial atypical multiple mole
melanoma (FAMMM) syndrome, but also a 15% to 20% lifetime
risk for developing PC [4]. Because many individuals with a specific
Dutch founder mutation in the CDKN2A gene (a 19-bp deletion
known as p16-Leiden) are living in the vicinity of Leiden, a relatively
large cohort of these patients is under pancreatic surveillance in the
LUMC. The surveillance program consists of annual abdominal
magnetic resonance imaging (MRI; and magnetic resonance
cholangiopancreatography [MRCP]) and optionally endoscopic
ultrasound (EUS). Although these screening modalities are generally
able to detect early-stage PC or relevant precursor lesions of PC, the
diagnostic yield of surveillance programs using these modalities varies
greatly, and only a subset of patients with a screen-detected PC has an
early-stage cancer [2,5]. Therefore, there is a need to improve the
current pancreatic surveillance program.
One way to improve PC surveillance programs is to use serum
biomarkers as an additional noninvasive screening modality [6–9].
These biomarkers have to discriminate cancer patients from
noncancer patients or even patients with precursor lesions of PC.
Currently, only the mucin-associated carbohydrate antigen CA 19-9
is routinely used but has not proven to be an adequate biomarker for
detecting early-stage PC [10]. Many studies have been published on
novel individual biomarkers for the early detection of PC, but none of
them have been implemented in daily practice so far [11,12].
In our center, a discriminating PC biomarker signature was
recently identified by following a serum peptide and protein profiling
strategy based on a combination of automated single-step sample
clean-up and matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-MS) [13,14]. The most detailed protein
signatures were obtained using an ultrahigh-resolution MALDI
Fourier transform ion cyclotron resonance (FTICR) MS platform
that provided case-control classifications with a sensitivity and
specificity both well above 85% [15]. A discriminating prediction
rule was validated for this classification. The methodology used in our
previous studies is graphically displayed in Figure 1 (left-hand side).
Based on these encouraging results, it was concluded that such
protein signatures are a promising candidate for implementation in
the current pancreatic surveillance program as an additional screening
modality. The aim of the current study is therefore to determine
whether ultrahigh-resolution protein profiling (using MALDI-F-
TICR MS) in serum can accurately distinguish individuals with PC
from non-PC in a novel cohort of CDKN2A mutation carriers
enrolled in the pancreatic surveillance program using the previously
designed and validated prediction rule for the classification of
individual samples (Figure 1, right-hand side).Patients and Methods
Patient Cohort and Blood Sampling
Individuals with a CDKN2A germline mutation who participate in
the pancreatic surveillance program at the LUMC were eligible for
inclusion. A complete medical history was obtained at the start of
surveillance, including a medical history of melanoma or other
cancers. Subsequently, annual MRI and MRCP with optionally EUS
were performed. and in case of an abnormal finding, either close
follow-up with MRI/MRCP and EUS or surgery was advised by a
multidisciplinary team, as previously described [3]. Any cancer
occurring in follow-up was registered. Cases were defined as having a
pathologically confirmed diagnosis of PC. Controls were not
diagnosed with PC and included individuals with relevant precursor
lesions of PC. These were defined as either pathologically proven
precursor lesions (intraductal papillary mucinous neoplasm [IPMN]
and pancreatic intraepithelial neoplasia [PanIN] [16]) or radiological
cystic lesions ≥5 mm suspicious for IPMN.
Serum samples from the cases with PC were obtained before surgery.
Serum samples from the controls without PC were obtained during
their annual surveillance visit at the outpatient gastroenterology clinic.
Only one sample was collected per individual. Samples were collected
over a time period ranging from April 2008 until January 2015.
Additional serum samples of CDKN2Amutation carriers with PC who
did not participate in the surveillance programwere available through an
ongoing research project of the Department of Surgery, in which serum
samples of all patients with PC are obtained before surgery. Samples
were collected and processed following a standardized high-throughput
clean-up protocol as previously described [17,18]. Informed consent
was obtained from all individuals, and the study was approved by the
Ethics Committee of the LUMC (#P03.147).
Sample Processing and MALDI-FTICR MS Peptide Profiling
The isolation of peptides and protein from serum was performed
using a fully automated, high-throughput protocol based on solid-phase
extraction with RPC18-funtionalized magnetic beads, as previously
described [15,18]. Subsequently, MALDI profiles were obtained on a
MALDI-FTICR platform that allows mass analysis of serum peptides
and proteins with isotopic resolution up to 15,000 Da. A detailed
description of this approach and workflow, as well as the subsequent
data processing, was previously described by Nicolardi et al. [15]. For
this study, only so-called low-mass data (i.e., up tom/z value 4000) were
used for statistical analysis. The serum samples were blindly analyzed.
Statistical Analysis
Our group previously designed a prediction rule to classify a serum
sample as either case or control using logistic regression ridge
shrinkage analysis [15,19]. By applying the same prediction rule to
the low-mass data acquired in this study, a “discriminant score” was
calculated for each sample. Samples were grouped according to their
known disease status, and the median discriminant scores per group
were compared using a Mann-Whitney-Wilcoxon test. Individuals
with precursor lesions and individuals with a recent diagnosis of
melanoma were also separately considered.
Results
Patients
A total of 66 individuals (42 females, 64%) were included in the
study. Sixty-one individuals had a molecularly proven CDKN2A
Figure 1. Serum peptide and protein profiling strategy aiming for patient classification based on MALDI-FTICR MS. Various peptide and
protein signatures have been reported based on a single-step sample clean-up procedure using a combination of a carrier (depicted in the
inner shell) with capture material (depicted in the middle shell) and a mass spectrometer (depicted in the outer shell). Previously, our
group has reported signatures for PC based onweak-cation exchangewithMALDI time-of-flight [13], and reversed-phase C18 withMALDI
time-of-flight [14]. In the current study, an ultrahigh-resolution reversed-phase C18-MALDI-FTICR signature is used that was obtained in a
case-control calibration and validation design (left-hand side) [15]. Serum samples from CDKN2A mutation carriers are analyzed in an
identical way to obtain a discriminant score (right-hand side).
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(c.225_243del19; RefSeq NM_000077.4). One individual carried
the c.67GNC mutation, which is also associated with PC (not
published data). The remaining five individuals had a medical history
of melanoma (or PC, #4 Table 2) and a close relative with a proven
CDKN2A germline mutation, which makes them highly likely of
being a carrier. Patient characteristics are shown in Table 1. Five
individuals (all female) had PC, with a mean age of 54 years (range 39
to 62 years). Two of five cases had a medical history of melanoma, but
no other cancers occurred in the case group. The remaining 61
individuals (37 females, 61%) had no PC. The mean age of the
control group was 53 years (range 42 to 72 years). Thirty-eight
controls had a medical history of melanoma, and a few other cancers
occurred in the control group (Table 1). One individual in the control
group had a melanoma 1 month before serum sampling (#2 Table 3),
and one individual had a melanoma 1 month after serum sampling.
Two other individuals had cancer ≤12 months before or after serum
sampling (both melanoma; 12 months prior and 9 months after).
These melanomas were nonmetastatic.
Detailed information about the case group is shown in Table 2.
Three cases were participating in the surveillance program, of which
two were diagnosed with PC at the first screening round (prevalent)
and one was diagnosed on a subsequent screening round (incident).
This latter individual (#1, Table 2) had a normal MRI 2 years earlier
but missed her MRI a year later. She was diagnosed with a 3.6-cm
tumor in the subsequent year. Two of five cases were not participatingTable 1. Patient Characteristics
Diagnosis No. of Patients Age (Range) M:F Medical Histor
PC 5 54 (39-62) 0:5 2 (1)
No PC 61 53 (42-74) 24:37 38 (12)
With precursor lesions 4/61 54 (45-63) 2:2 3 (1)
Total 66 53 (39-74) 24:42 40 (13)
* None of these cancers occurred within a year before serum sampling.
† These cancers occurred synchronously in one individual.in the surveillance program and had their serum drawn before surgery
as part of standard (research) procedure at the Department of Surgery.
Four individuals in the control group had relevant precursor lesions
of PC, of which detailed information is shown in Table 3. All four
individuals had cystic lesions ≥5 mm suspicious for IPMN, but only
one individual had a surgical resection due to growth of the lesion.
Pathological examination of the resected pancreas of this patient
confirmed the presence of an IPMN lesion, as well as multifocal
PanIN1-2 lesions.
Statistical Classification of Serum Profiles
High-quality MALDI-FTICR data were obtained from all samples,
and therefore all samples were suitable for further statistical analysis.
In Figure 2, boxplots of the calculated discriminant scores for cases
(n = 5) and controls (n = 61) are shown. Boxplots of the data from our
previous study are displayed in Figure 2 as well. Cases from our
previous study had a noticeably higher score than cases from the
current study, as can be seen in Figure 2. This can probably be
explained by the fact that more cases in our previous study had
metastatic (lymph nodes positive or distant) disease, i.e., stage IIB or
higher (83% compared with 60% in the current study). As was shown
in our previous study, a more advanced tumor stage is associated with
a higher discriminant score. The difference could further be caused by
a systematic recalibration effect. Nonetheless, the boxplots show that
cases with PC are accurately distinguished from controls without PC
in the new surveillance data. The median discriminant score is 0.26y of Melanoma (of which Multiple) Medical History of Other Cancers (# of Individuals) *
None
Squamous cell carcinoma of larynx (1) †
Squamous cell carcinoma of mouth (1) †
Squamous cell carcinoma of skin (1)
Basal cell carcinoma of skin (3)
Phyllodes sarcoma of breast (1)
None
As above
Table 2. Tumor Characteristics of Cases with PC
Age M/F Medical History
of Cancer
Mode of
Diagnosis
Localization Tumor
Size
Tumor Stage
(TNM)
Tumor
Grade
1 57 F – Surveillance,
incident
Tail 3.6 T2N0M0
(Stage IB)
2
2 62 F Me 56 yrs Surveillance,
prevalent
Head-corpus 0.5 T1N0M0
(Stage IA)
1
3 62 F Me 31 yrs (2×) Symptomatic Head 5.0 T3N1M0
(Stage IIB)
2
4 39 F – Symptomatic Proc.
uncinatus
1.5 T3N1M0
(Stage IIB)
n/a
5 47 F – Surveillance,
prevalent
Corpus 5.7 T3N1M0
(Stage IIB)
3
Me = melanoma.
Figure 2. Boxplots of the discriminant scores for cases and
controls of the current study and of our previous study. The
boxplots on the left represent the data of the current study. For
comparison, boxplots of the data from our previous study [15] are
displayed on the right. The generally higher discriminant scores of
cases in the previous study compared with cases in the current
study can probably be explained by the fact that more cases in our
previous study had metastatic (lymph nodes positive or distant)
disease, i.e., stage IIB or higher (83% compared with 60% in the
current study). A more advanced tumor stage is associated with a
higher discriminant score. A systematic recalibration effect could
further explain the difference.O = outliers.
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.001 using the Mann-Whitney-Wilcoxon test).
Scores of individuals with precursor lesions of PC are separately
shown in Figure 3. The only individual with pathologically proven
precursor lesions of PC (#1 in Table 3, * in Figure 3) had a relatively
high score of 0.34, well above the median score of controls and
comparable with the scores of the cases. The individual with precursor
lesions as well as a melanoma 1 month before serum sampling (#2 in
Table 3, † in Figure 3) had a score of 0.08 and scored above the 75th
percentile of the median score of the control group. The other two
individuals with (radiological) precursor lesions had a score below the
median of the control group. Apart from individual #2 (Table 3),
there were three other individuals with a melanoma diagnosed shortly
before or after serum sampling. These individuals had a score near or
well below the median score of the control group.
Discussion
In this study, we analyzed biomarker profiles in a pancreatic
surveillance cohort of CDKN2A mutation carriers with and without
PC using the same methodology as in our earlier work. By applying
the previously designed prediction rule for the classification of serum
samples, cases with PC could be accurately distinguished from
controls without PC. Also, individuals with suspicious precursor
lesions of PC might be distinguished from controls, and having aTable 3. Precursor Lesions of PC in the Control Group
Age M/
F
Medical History
of Cancer
Findings Pancreatic Surveillance Surgical
Intervention
Pathology
1 63 F – Multicystic lesion of 15 mm in
head-corpus region, stable for 6
years and growth to 17 mm in
the 7th year. Suspicious for
BD-IPMN.Two cystic lesions
(8 mm, head and 5 mm, tail),
stable for 2 years. Suspicious for
BD-IPMN
Subtotal
pancreatectomy
BD-IPMN;
multifocal
PanIN1-2
2 59 M N15 Me from
age 27, most
recent at age 59
Multicystic lesion of 7 mm in
proc. uncinatus, suspicious for
BD-IPMN, stable for 2 years
Not performed n/a
3 45 F Me 42 yrs Cystic lesion of 7 mm and
multicystic lesion of 7 mm in
head region, both suspicious for
BD-IPMN, stable for 2 years
Not performed n/a
4 49 M Me 44 yrs Cystic lesion of 13 mm in
corpus-tail region, suspicious
for BD-IPMN, stable for 2 years
Not performed n/a
BD-IPMN = branch duct intraductal papillary mucinous neoplasma.(medical history of) melanoma probably does not influence the
protein signatures. Protein profiling therefore has potential to be
included in the pancreatic surveillance program, where it, as an
addition to current screening methods, can aid in the decision of
whether a patient will need surgery or not.Figure 3. Scatter plot of the discriminant scores of the current
study; individuals with precursor lesions are separated from
controls. This figure shows all the individual discriminant scores
of the 66 included individuals, subdivided in cases (n= 5), controls
(n = 57), and individuals with precursor lesions (n = 4).* Individual
#1 (Table 3), discriminant score of 0.34; † Individual #2 (Table 3),
discriminant score of 0.08.
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patient cohorts over the last decades [12,20,21], but this is the first
study to investigate the role of biomarkers in a pancreatic surveillance
cohort of genetically predisposed individuals. Recent studies from the
University of Marburg did however investigate biomarkers in familial
PC (FPC) individuals with PC or relevant precursor lesions of PC in a
nonsurveillance setting [22,23]. Interestingly, the (few) individuals
with pathologically confirmed high-grade precursor lesions (PanIN 2/
3) in their studies had significantly elevated serum biomarker levels
before surgery, and the levels dropped to the normal range after
surgery. FPC individuals having relevant precursor lesions of PC
could thus accurately be distinguished from healthy controls using
their proposed biomarker sets, and the authors argued that
biomarkers may be suitable for the early detection of precursor
lesions of PC in high-risk individuals.
Indeed, a major goal of screening is the detection of precursor
lesions of PC [2], and their prevalence in CDKN2A mutation carriers
is evident. Vasen et al. reported that 11% of CDKN2A carriers in the
surveillance program had possible precursor lesions (ductectasias) on
radiology [3]. Potjer et al. reported an even higher number (16%) and
concluded that precursor lesions might have a high malignant
potential in CDKN2A carriers compared with precursor lesions in
FPC individuals [24]. To be implemented in a pancreatic surveillance
cohort, it is therefore important that potential serum biomarkers
distinguish noncancer patients not only from cancer patients but
also from patients with relevant precursor lesions of PC. In this
study, there was only one patient with histologically confirmed
precursor lesions (IPMN and PanIN1-2), and as mentioned, those
precursor lesions, especially the IPMN, might have a relatively
high malignant potential because the patient was a CDKN2A
mutation carrier. This patient had a protein signature comparable to
those with PC. The other three patients with less suspicious precursor
lesions on radiology had a normal to near-normal protein profile.
Therefore, it seems likely that patients with substantial precursor
lesions might be accurately distinguished from healthy CDKN2A
carriers using serum protein profiling, although numbers are too small
to make definite conclusions.
A second requirement for biomarkers to be implemented in a
pancreatic surveillance cohort of high-risk individuals, especially
CDKN2A carriers, is that the signatures are not disturbed by the
occurrence of other types of cancer. The FAMMM syndrome (due to
a CDKN2A germline mutation) is mainly characterized by a very high
risk (70%) of developing cutaneous melanoma, and 62% of the
carriers in this study indeed had a medical history of melanoma.
Having a medical history of melanoma did not influence the protein
signatures in general, as cases could still accurately be distinguished
from controls in this cohort. Also, the four controls with a recent
diagnosis of melanoma did not evidently diverge from the other
control patients. Only the individual with both a recent diagnosis of
melanoma and radiological precursor lesions had a slightly higher
discriminant score than the other controls, but that could be caused
by the presence of precursor lesions as argued above. In addition to
the high risk of developing melanoma and PC, CDKN2A mutation
carriers also have a higher risk of developing head and neck squamous
cell carcinoma, which emphasizes that FAMMM syndrome is a true
tumor syndrome [25,26]. It is therefore also important to know if
these cancers influence the protein signatures, but that could not be
investigated in the current study due to the fact that there was no
recent diagnosis of this type of cancer in the study group. There wasonly one individual in this cohort with two synchronous tumors of
the larynx and mouth 4 years before serum sampling, without
recurrence after treatment and a very low discriminant score.
The most important limitation of this study is sample size. More
individuals with PC and, preferably, histologically confirmed high-
grade precursor lesions are needed to investigate if these individuals
definitely can be distinguished from healthy CDKN2A individuals.
These patients are however very rare, and it would take years to collect
only a few more patients. Also, more patients with other tumors than
PC at or around the time of serum sampling are needed to investigate
if those tumors intervene with the protein signatures. A second
limitation is that we did not collect samples after surgical treatment,
and therefore we could not investigate if the high discriminant scores
declined after surgery. Future implementation of protein profiling in
the surveillance program, with standardized yearly serum sampling,
including postsurgery sampling, will ensure more patients with
different types of cancer or precursor lesions of PC.
Because current screening strategies for PC are not entirely reliable
for detecting early-stage PC or its (high-grade) precursor lesions, there
is a strong need to improve the pancreatic surveillance program. As is
shown in this preliminary study, protein profiling seems to be a very
promising method to be included as an additional noninvasive
screening modality. Previously, similar MS-based profiling studies in
our group provided promising results with regard to peptide and
protein signatures for the early detection of breast cancer and
colorectal cancer [18,27], and thus protein profiling seems suitable for
cancer surveillance in general.
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